Kornimate/medical-research-clean huggingface dataset:
a tool for improving the shared decision-making process in patients with non-small cell lung cancer

Conditions: Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8

Summary: this clinical trial compares the use of a shared decision-making communication tool during a clinical encounter to standard care for improving the quality of the shared decision-making process among patients with non-small cell lung cancer. lung cancer patients are faced with many decisions about their treatment options. studies have found that patients are most satisfied if they perceive an effort by their physician to share decision making and are afforded sufficient time to make their decision. shared decision-making tools can help physicians guide the conversation, offer tailored estimates of the potential benefits, harms, and practical inconveniences of the available options, and support deliberations that take into account patient biological and biographical circumstances, goals, and priorities. incorporating a shared decision-making communication tool into standard clinical encounters may improve the shared-decision making process as well as patient satisfaction with their treatment choice.

primary objectives: i. encounters where standard of care and the non-small cell lung cancer (nsclc) choice conversation aid were utilized will have an improvement in the quality of the shared decision-making process over encounters with standard of care alone. ii. patients with encounters where the nsclc choice conversation aid was used along with standard of care will have decreased decisional conflict in regard to treatment choice compared to standard of care alone. outline: patients are randomized to 1 of 2 arms. arm i: patients attend a standard of care visit with their clinician on study. arm ii: patients attend a standard of care visit with the use of the shared decision-making conversation tool by the clinician on study. after completion of study intervention, patients are followed up at 2 and 6 weeks.

Eligibility criteria:
inclusion criteria: * clinicians: * all clinicians within identified departments participating are eligible (doctor of medicine \[md\]/doctor of osteopathy \[do\], fellows/residents, physician assistant \[pa\]/nurse practitioner \[np\]) * patients: * adult patients (\>= 18 years of age) * appointments at mayo clinic in rochester * non-small cell lung cancer (nsclc) stage \> 1b * eligible by their oncologist for adjuvant treatment exclusion criteria: * exclude patient with major barriers to provide written informed consent or to participate in shared decision-making (i.e., dementia, severe hearing or visual impairment)
the effect of dimenhydrinate on postoperative nausea and vomiting after abdominal hysterectomy: randomized-controlled trial

Conditions: Gynecologic Neoplasm; Healthy Women

Summary: the aim of this clinical trial is to learn if dimenhydrinate works to prevent postoperative nausea-vomiting in adult women who undergoing abdominal hysterectomy. the primary question is: does dimenhydrinate lower the proportion of postoperative nauseavomiting during the day 1 after surgery. researcher will compare dimenhydrinate to a placebo (a-look-alike substance that contains no drug) which will give intravenously when the patient come back to the ward, to see if dimenhydrinate work to prevent nauseavomiting during the postoperative day1. all participants will receive standard treatment during pre-operative, intra-operative and the immediate post-operative periods. participants will receive dimenhydrinate or placebo only one dose after discharge from the recovery room. during the day 1 postoperative, participants will report their symptoms and keep a diary of the number of tmes they use additional anti-emetic drugs.


Eligibility criteria:
inclusion criteria: * 18-65 years female * undergoing trans abdominal hysterectomy exclusion criteria: * undergoing emergency surgery * pregnancy or breastfed women * post delivery less than 6 weeks * history of allergic reaction or precaution to use the protocol drug * bmi less than 18 or more than 30 kg/m2 * need icu care after surgery

Keywords: post-operative nausea vomiting
accurate diagnosis system for postoperative chronic pain based on fmri

Conditions: Chronic Pain; Mammary Cancer

Summary: postoperative pain is an ideal model for study on acute pain changing into chronic pain. the functional imaging of magnetic resonance can reflect the extent and character of pain exactly and the structural imaging of it can be a sign of the change. by analyzing fmri results of participants with acute pain and following them up for three months, the investigators expect to find objective indicators for acute pain changing into chronic pain and give preventive analgesia for people with high risk of chronic pain.

the day before surgery, evaluate and choose patients according to inclusion and exclusion criteria. use the same anaesthesia and management and record information needed by the case report format. patients are examined by fmri on their brains during the first week after surgery. follow up the patients after surgery for three months to find out whether they have chronic pain. the nrs, dn4, id pain and qlq-c30 are used for each patient.

Eligibility criteria:
inclusion criteria: * junior high school degree or above * can be communicated in mandarin normally * selective operation of mastectomy with or without axillary lymph node dissection * similar operation method and incision size * bmi between 18 and 30 * asa grade i-ii；informed consent exclusion criteria: * with brain disease or with brain disease history * opioid allergy * with claustrophobia * with history of chronic pain * with psychological or emotional problems * serious hearing or visual impairment * those who refuse to participant in this study
a study of sb-743921 in non-hodgkin lymphoma and hodgkin lymphoma

Conditions: Non-Hodgkin's Lymphoma; Hodgkin's Disease

Summary: this study was an early-phase trial arranged into two phases. the phase i portion was a dose-escalation study designed to assess the safety, tolerability and to identify the maximum tolerated dose of sb-743921 in patients with non-hodgkin lymphoma and hodgkin lymphoma. phase ii was intended to assess the activity, safety and tolerability of sb-743921 in patients with indolent and aggressive non-hodgkin's lymphomas exclusively. the phase ii portion of the study was not initiated.


Eligibility criteria:
inclusion criteria: phase 1: patients with evaluable or measurable (by mri or ct) hodgkin's disease or non-hodgkin's lymphoma. phase 2: patients with measurable non-hodgkin's lymphomas (indolent or aggressive) only. - patients with indolent nhl must be relapsed or refractory to at least one prior line of therapy (chop, cvp, chlorambucil or fludaribine). prior treatment with rituximab is required. - patients with aggressive nhl refractory to (or relapsed from) at least one chop-based therapy who have had prior treatment with rituximab and who are not candidates for high-dose chemotherapy or autologous stem cell transplantation. - ecog performance status 0-2 - autologous stem cell transplant recipients are eligible if 100 days have elapsed since procedure. exclusion criteria: phase 1: history of prior radioimmunotherapy (bexxar, zevalin); these patients are permitted in the phase 2 trial. - current active malignancy besides nhl, except excised non-melanoma skin cancer, in-situ cervical or bladder cancer or early stage prostate cancer. - patients with leptomeningeal of cns lymphoma - known allergy to and/or receipt of treatments contraindicated by administration of g-csf - patients with active hepatitis b or c, or patients with hiv infection. - pregnant or breast-feeding females. - previous treatment with a ksp inhibitor
change in foveal avascular zone after removal of epiretinal membrane and internal limiting membrane

Conditions: Epiretinal Membrane

Summary: fovea is characterized by its vessel-free zone, called foveal avascular zone and it can be visualized by fluorescein angiography. removal of epiretinal membrane and internal limiting membrane is frequently performed procedure and we suspected that these procedures may affect integrity of foveal avascular zone. the purpose of the present study is to evaluate the change of foveal avascular zone after removal of epiretinal membrane and internal limiting membrane


Eligibility criteria:
inclusion criteria: * epiretinal membrane exclusion criteria: * history of vitrectomy, intraocular surgery * any macular disease other than epiretinal membrane * media opacity obscuring the image of fluorescein angiography

Keywords: epiretinal membrane foveal avascular zone internal limiting membrane
safety trial of nk dli from 6/6 hla matched family member following nonmyeloablative asct

Conditions: Lymphoma

Summary: evaluate the safety of natural killer (nk) cell infusion using cd56 monoclonal antibody selected with miltenyi biotec system following nonmyeloablative stem cell transplantation (sct) from matched donors. this pilot study will evaluate toxicity including mortality, occurrence of acute graft versus host disease and other severe toxicity.

the use of non-selected donor lymphocyte infusions (dlis) (to help early immune recovery and induce antitumor response) following nonmyeloablative allogeneic stem cell transplantation (asct) is also complicated by the risk of acute graft versus host disease (agvhd) with 30-40% of patients experiencing grade iii-iv agvhd. data suggests that the use of natural killer (nk) cells (instead of nonselected dlis) in this setting may mediate a graft versus tumor (gvt) effect independently of agvhd. this pilot study is designed to evaluate the efficacy and toxicity of donor natural killer (nk) cell selection and infusion following nonmyeloablative allogeneic stem cell transplantation (asct) from matched donors.

Eligibility criteria:
inclusion criteria: * patients with who have undergone a non-myeloablative allogeneic transplant, using a 6/6 human leukocyte antigen (hla) matched sibling donor. measureable disease is not needed at study entry. * performance status must be karnofsky 50-100%. * donor cellular engraftment of at least 2.5% from the non-myeloablative procedure. * ≤ grade 2 acute graft versus host disease (agvhd) at time of infusion of natural killer (nk) cell infusion. patients with treated agvhd must be on a stable dose of therapy (no increase in immunosuppressive therapy for the 2 weeks before planned natural killer cell infusion \[nki\]). the dosage/level of immunosuppressive therapy at the time of nki should be no greater than 1 mg/kg of prednisone daily or mycophenolate 1000 mg bid daily or cyclosporine with a target level of 200 or equivalent. * estimated survival at least 8 weeks. * age \> or equal to 18 years of age. exclusion criteria: * pregnant or lactating women, * patients with other major medical or psychiatric illnesses, which the treating physician feels, could seriously compromise tolerance to this protocol. * patients who had biopsy proven overall grade 4 gvhd lasting longer than 7 days, from the non-myeloablative therapy, are not eligible

Keywords: stem cell transplant matched donor nk infusion
efficacy of interferon-gamma in combination with anidulafungin for the treatment of candidemia

Conditions: Candidemia

Summary: the purpose of this study is to assess the feasibility and preliminary efficacy of interferon-gamma in combination with anidulafungin for the treatment of candidemia


Eligibility criteria:
inclusion criteria: * males or non-pregnant females (who must agree to use barrier methods of contraception during the study therapy period, women of childbearing age must have a negative urine pregnancy or serum test at baseline). * subjects who are 18 years of age or older * subjects with at least one positive blood culture isolation of candida species from a specimen drawn within 96 hours prior to study entry. * subjects who have clinical evidence of infection at some time within 96 hours prior to enrollment, including at least one of the following: * temperature \>37.8 ˚c on 2 occasions at least 4 hours apart or one measurement \> 38.2 ˚c * systolic blood pressure \ 30 mmhg decrease in systolic bp from the subject's normal baseline. * signs of inflammation (swelling, heat, erythema, purulent drainage) from a site infected with candida (eg, joint, skin, eye, bone, esophagus) * radiologic findings of invasive candidiasis * subject or their legal representative must sign a written informed consent form. exclusion criteria: * subjects with a history of allergy or intolerance to echinocandins or ifngamma * subjects with a history of documented epileptic seizures * subjects with severe renal impairment (creatinine clearance less than 30/ml/min) * subjects with severe liver failure (impaired synthesis of proteins such as coagulation factors manifested by increased prothrombin time) * subjects with an absolute neutrophil count of less than 500/mm3 at study entry * women who are pregnant or lactating * subjects who are unlikely to survive more than 24 hours * subjects who have failed previous systemic antifungal therapy for the candida spp. infection which is being studied. * subjects who have received more than 48 hours of systemic antifungal therapy for the current episode, within 96 hours prior to study entry

Keywords: candidemia candida sepsis invasive fungal disease
the effect of motivational interviews

Conditions: Infertility, Female

Summary: the aim of the study was to determine the effect of motivational interviews applied to infertile women on their ability to cope with infertility, self-efficacy and stress.

there is no study in the literature on the effectiveness of motivational interviewing on being affected by infertility, self-efficacy and coping with stress. it is important for healthcare personnel to be easy to apply and short-term, to be aware of the effectiveness of the motivational interviewing technique, and to use this technique in communicating with the patient and changing behavior. based on these, it was deemed necessary to examine the effect of motivational interviews for infertile women.

Eligibility criteria:
inclusion criteria: * ages 18 and over and have no problems communicating those who have not previously or currently been diagnosed with a psychiatric disease infertile women who volunteer will be included in the sample of the research exclusion criteria: * pregnancy during the study, having previously or currently participated in a motivational interviewing program, those who want to leave the research, not completing motivational interviewing sessions, infertile women with any deficiencies or errors in any of the forms from which the data are obtained will be excluded from the sample.

Keywords: infertility motivational interview stress
a phase2 clinical trial of trafermin in patients with marginal periodontitis in japan

Conditions: Periodontitis

Summary: this study is designed to evaluate the efficacy and the safety of trafermin(recombinant human basic fibroblast growth factor: rhbfgf) in japanese patients with marginal periodontitis, in order to verify the superiority of trafermin to placebo, and to determine the recommended therapeutic dose.


Eligibility criteria:
inclusion criteria: the patient with marginal periodontitis intend to conduct a flap operation(modified widman) must meet the following criteria: * alveolar bone defect diagnosed by radiography. * mobility of teeth must be \<=2 and the width of attached gingiva is suitable for gtr(guided tissue regeneration) method. * males and females, \>=20 years of age. exclusion criteria: patients will be excluded from the study if any of the following conditions are present: * concomitant administration of adrenal cortical steroid within 4weeks of treatment in the trial. * current or previous history of gingival overgrowth by drugs. * current or previous history of cancer or malignant tumour. * presence of diabetes mellitus(hba1c\>=6.5%) * presence of malnutrition(serum albumin\<=2g/dl) * pregnancy or lactation

Keywords: trafermin periodontitis
transcutaneous carbon dioxide monitoring post cardiac surgery: incidence and severity resp insufficiency

Conditions: Respiratory Insufficiency

Summary: the purpose for the investigators study is to investigate the severity and incidence of respiratory insufficiency using transcutaneous carbon dioxide (tcpco2) monitoring as an adjunct to the current standard of care for early detection of inadequate ventilation in post-operative surgical in-patients undergoing cardiac surgery after discharge from intensive care unit (icu) or post anesthesia recovery unit (pacu).

this observational study is to determine the baseline carbon dioxide and severity of respiratory distress and acute respiratory failure (arf)/respiratory arrest in the post cardiac surgery patients in the first 24 hours on a monitored telemetry floor.

Eligibility criteria:
inclusion criteria: * asa class 1, 2, 3, or 4 men and women who are having cardiac surgery by one of the participating surgeons exclusion criteria: 1. subject has participated in a trial with any experimental drug or device trial within 30 days prior to enrollment in the study, or has ever been enrolled in this study; 2. subject has a condition that would require an extensive amount of time off of 13 roberts during the first 24 hours of admission to the telemetry unit. (e.g., hemodialysis); 3. subject has a condition or allergy which would prohibit placing the probe on the earlobes; 4. subject is unable to undergo any procedure required by the protocol; 5. subject has any other condition or factor which, in the investigator's opinion, might increase the risk to the subject; or 6. if female, subject is non-lactating, and is either: * not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile due to bilateral tubal ligation, bilateral oophorectomy, or hysterectomy; or * of childbearing potential but is not pregnant as confirmed by negative serum pregnancy test at time of screening.

Keywords: post operative respiratory insufficiency
study of efficacy and safety of brodalumab compared with placebo in adults with inadequately controlled asthma with high bronchodilator reversibility

Conditions: Asthma

Summary: the purpose of this study is to determine if brodalumab (amg 827) is safe and effective compared to placebo as measured by change in asthma control questionnaire (acq) composite scores.


Eligibility criteria:
inclusion criteria: * diagnosis of asthma, and presently has reversibility over pre-bronchodilator forced expiratory volume in 1 second (fev1) of ≥ 20% at screening * percent of predicted fev1 ≥ 40% and ≤ 80% at screening * inhaled corticosteroid (ics) ≥ 200 and ≤ 1000/μg/day fluticasone powder or equivalent * ongoing asthma symptoms with asthma control questionnaire (acq) composite score at screening and baseline ≥ 1.5 points exclusion criteria: * history of chronic obstructive pulmonary disease (copd) or other chronic pulmonary condition other than asthma * history of allergic bronchopulmonary aspergillosis * respiratory infection within 4 weeks of screening or 1 week of baseline visit * subject has known history of crohn's disease * subject has any other significant concurrent medical condition of laboratory abnormalities, as defined in the study protocol * subject has previously used any anti-interleukin-17 (il17) biologic therapy * subject is pregnant or breastfeeding, or planning to become pregnant while enrolled in the study * female subject is unwilling to use highly effective methods of birth control unless 2 years post-menopausal or surgically sterile * subject has severe depression measured by personal health questionnaire depression scale (phq-8) or suicidal ideation/behavior as measured by and columbia suicide severity rating scale (e-cssrs) * subject has a history or evidence of psychiatric disorder or substance abuse considered by the investigator to pose a risk to subject safety

Keywords: inadequately controlled asthma, brodalumab, amg 827
cardiac remodeling and circulating biomarkers in pediatric left ventricular pressure loading lesions

Conditions: Coarctation of Aorta; Aortic Stenosis; Cardiac Hypertrophy

Summary: this study is designed to learn more about children who have blockage of the left side of their heart. the goal is to determine how much the heart muscle has thickened before surgery and how it changes in the months after surgery. investigators are also looking for blood tests that may help them predict which patients will have the most thickening pre-operatively and the best return towards normal after surgery. the findings of this study will help the investigators develop new tests to monitor affected patients and develop new therapies to help minimize heart thickening.


Eligibility criteria:
inclusion criteria: * congenital heart disease patients with the following diagnoses undergoing surgical repair: coarctation of the aorta (coa), aortic stenosis (as), subaortic membrane (sub-as), supravalvar aortic stenosis (supra-as). * all patients will have age from birth through 18 years of age. * while we will generally not enroll patients with other co-morbid heart disease that would alter the cardiac physiology (see exclusion criteria), patients with patent foramen ovale, atrial septal defect, and patent ductus arteriosus specifically will be allowed. exclusion criteria: * patients with lesions not listed in inclusion criteria (including but not limited to hypoplastic left heart syndrome, shone's complex, mitral valve stenosis or regurgitation greater than trivial, non-restrictive ventricular septal defect, interrupted aortic arch, atrio-ventricular canal defect) * corrected gestational age at time of surgery \<34 weeks * weight at time of surgery \<2000g. * patients who will not be seen for any follow-up care at children's hospital colorado

Keywords: coarctation of aorta aortic stenosis biomarkers cardiac hypertrophy
self-help application for eating disorder

Conditions: Eating Disorder in Adolescents and Young Adults

Summary: the purpose of this study is to determine whether mobile-based self-help cbt-e treatment for eating disorder can reduce eating disorder symptoms compared to the waitlist group


Eligibility criteria:
inclusion criteria: 1. aged 13-22 years 2. owns a smartphone 3. experienced at least one episode of binge eating over the past 4 weeks exclusion criteria: 1. diagnosed with anorexia nervosa 2. bmi ≤ 17.5 3. having developmental disabilities, including autism, intellectual disabilities, schizophrenia, or other psychosis
immunity against aav in crigler najjar patient

Conditions: Crigler Najjar Syndrome

Summary: the proposed research protocol aims at addressing these points by pre-screening cn patients for their aav serology in link with their medical history and current medical status. a first objective is to assess the presence of neutralizing aav antibodies in the serum of cn patients.


Eligibility criteria:
inclusion criteria: * the patient has a crigler-najjar syndrome * the molecular diagnosis has been confirmed by ugt1a1 gene dna sequencing exclusion criteria: * the patient is liver transplanted * the patient is suffering from severe associated pathologies precluding further enrolment in a future interventional clinical study